ストックスクリーナーアプリを入手
7.675
10.96%
-0.945
アフターアワーズ：
7.66
-0.015
-0.20%
前日終値:
$8.62
開ける：
$8.62
24時間の取引高:
1.02M
Relative Volume:
1.64
時価総額：
$237.93M
収益：
-
当期純損益:
$-29.25M
株価収益率:
-6.4713
EPS:
-1.186
ネットキャッシュフロー:
$-22.80M
1週間 パフォーマンス:
+5.28%
1か月 パフォーマンス:
+7.64%
6か月 パフォーマンス:
+244.17%
1年 パフォーマンス:
+85.39%
1日の値動き範囲:
$7.665
$8.675
1週間の範囲:
$7.1145
$8.76
52週間の値動き範囲:
$1.73
$11.41
Sagimet Biosciences Inc Stock (SGMT) Company Profile
名前
Sagimet Biosciences Inc
セクター
電話
(650) 561-8600
住所
155 BOVET RD., SUITE 303, SAN MATEO
SGMT を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
SGMT
Sagimet Biosciences Inc
|
7.675 | 280.34M | 0 | -29.25M | -22.80M | -1.186 |
|
VRTX
Vertex Pharmaceuticals Inc
|
407.79 | 106.37B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
460.46 | 59.90B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
564.63 | 60.40B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
796.92 | 49.56B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
320.10 | 36.88B | 4.56B | -176.77M | 225.30M | -1.7177 |
Sagimet Biosciences Inc Stock (SGMT) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-08-11 | 開始されました | Wedbush | Outperform |
| 2025-08-07 | 再開されました | H.C. Wainwright | Buy |
| 2025-07-24 | 開始されました | Canaccord Genuity | Buy |
| 2024-12-06 | 開始されました | Oppenheimer | Outperform |
| 2024-11-12 | 開始されました | UBS | Buy |
| 2024-06-28 | ダウングレード | Goldman | Buy → Neutral |
| 2024-05-02 | 開始されました | H.C. Wainwright | Buy |
| 2024-03-25 | 開始されました | Leerink Partners | Outperform |
| 2023-08-08 | 開始されました | Goldman | Buy |
| 2023-08-08 | 開始されました | JMP Securities | Mkt Outperform |
| 2023-08-08 | 開始されました | Piper Sandler | Overweight |
| 2023-08-08 | 開始されました | TD Cowen | Outperform |
すべてを表示
Sagimet Biosciences Inc (SGMT) 最新ニュース
Sagimet Biosciences Inc. stock retracement – recovery analysisEarnings Risk Report & Verified Trade Idea Suggestions - newser.com
Is a relief rally coming for Sagimet Biosciences Inc. holdersJuly 2025 Market Mood & Proven Capital Preservation Methods - newser.com
Is Sagimet Biosciences Inc. forming a reversal pattern2025 Momentum Check & Consistent Profit Trading Strategies - newser.com
Using flow based indicators on Sagimet Biosciences Inc.July 2025 Decliners & Capital Efficient Trade Techniques - newser.com
Has Sagimet Biosciences Inc. found a price floorAnalyst Upgrade & Stock Market Timing Techniques - newser.com
Developing predictive dashboards with Sagimet Biosciences Inc. dataWeekly Profit Summary & Reliable Intraday Trade Alerts - newser.com
Will Sagimet Biosciences Inc. (0O2) stock justify high valuationWeekly Investment Recap & Risk Controlled Daily Trade Plans - newser.com
Viking Therapeutics, Genfit, Sagimet jump as Novo to buy Akero - MSN
Viking, Genfit, Sagimet jump on Novo- Akero deal (AKRO:NASDAQ) - Seeking Alpha
Sagimet Biosciences' (SGMT) Sell (D-) Rating Reiterated at Weiss Ratings - MarketBeat
Sagimet Biosciences Inc. (NASDAQ:SGMT) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
Will Sagimet Biosciences Inc. benefit from macro trends2025 Key Lessons & Smart Money Movement Tracker - newser.com
Denifanstat Advances: Sagimet Builds Momentum Toward 2026 Readouts (NASDAQ:SGMT) - Seeking Alpha
Sagimet Biosciences to Present Positive Results for Denifanstat in Advanced Fibrosis at AASLD 2025 - Quiver Quantitative
Sagimet Biosciences Announces Upcoming Presentation at AASLD—The Liver Meeting® 2025 - GlobeNewswire
≥2‑Stage Fibrosis Improvement: Sagimet denifanstat data to be presented at AASLD 2025 - Stock Titan
Using Ichimoku Cloud for Sagimet Biosciences Inc. technicalsPortfolio Update Summary & AI Forecast for Swing Trade Picks - newser.com
Why analysts recommend Sagimet Biosciences Inc. (0O2) stock2025 Geopolitical Influence & Smart Money Movement Tracker - newser.com
Using data tools to time your Sagimet Biosciences Inc. exit2025 Risk Factors & Daily Stock Trend Watchlist - newser.com
Is Sagimet Biosciences Inc. stock ready for a breakoutJuly 2025 Final Week & Low Drawdown Trading Strategies - newser.com
Sagimet Biosciences (NASDAQ:SGMT) Given “Buy” Rating at Canaccord Genuity Group - Defense World
Risk vs reward if holding onto Sagimet Biosciences Inc.Trade Entry Summary & Fast Gaining Stock Strategy Reports - newser.com
Has Sagimet Biosciences Inc. formed a bullish divergenceExit Point & Safe Entry Trade Signal Reports - newser.com
Applying big data sentiment scoring on Sagimet Biosciences Inc.Gap Down & Weekly Market Pulse Alerts - newser.com
Canaccord Genuity Maintains Sagimet Biosciences (SGMT) Buy Recommendation - Nasdaq
Canaccord Genuity Group Reiterates Buy Rating for Sagimet Biosciences (NASDAQ:SGMT) - MarketBeat
Buy Rating for Sagimet Biosciences: Promising Clinical Developments and Synergistic Therapy Potential - TipRanks
Goldman Sachs Group Inc. Sells 109,464 Shares of Sagimet Biosciences Inc. $SGMT - Defense World
Sagimet Biosciences Inc Stock Analysis and ForecastInsider Selling Patterns & Minimal Investment Portfolio Growth - earlytimes.in
Published on: 2025-10-01 08:26:59 - newser.com
Sagimet Biosciences Inc. Announces Dosing of First Participants in Phase 1 PK Clinical Trial for Denifanstat and Resmetirom Combination - MarketScreener
Sagimet announces dosing in Phase 1 PK trial of denifanstat with resmetirom - TipRanks
Sagimet Biosciences Initiates Phase 1 Trial for Combination Therapy Targeting Metabolic Dysfunction-Associated Steatohepatitis - Quiver Quantitative
Sagimet Biosciences Announces Dosing of First Participants - GlobeNewswire
Novel MASH Drug Combination: Sagimet Launches Phase 1 Trial for Denifanstat-Resmetirom Treatment - Stock Titan
Sagimet Biosciences Announces Dosing of First Participants in Phase 1 PK Clinical Trial for Denifanstat and Resmetirom Combination - Sahm
Kranti Industries Limited (542459) Expands into New MarketSupport Level Holds & Low Entry Cost Investment - earlytimes.in
Is Sagimet Biosciences Inc a good long term investmentStock Liquidity Analysis & Outstanding Growth Portfolio - earlytimes.in
What Price to Sales Ratio Tells Us About Tridhya Tech LimitedDebt-to-Equity Ratio Analysis & Low Risk Trading Ideas - earlytimes.in
Sagimet Biosciences Inc (SGMT) 財務データ
収益
当期純利益
現金流量
EPS
Sagimet Biosciences Inc (SGMT) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Martins Eduardo Bruno | Chief Medical Officer |
Jul 21 '25 |
Sale |
9.13 |
8,277 |
75,607 |
106,936 |
| Rozek Elizabeth | General Counsel and CCO |
Jul 21 '25 |
Sale |
9.13 |
10,780 |
98,471 |
183,726 |
5.74%
大文字化:
|
ボリューム (24 時間):